Oxcarbazepine Tablet
Product Images NDC 72888-460

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 72888-460). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxcarbazepine 150mg (Oxcarbazepine Tablets Usp 150mg 100s)

Label for Oxcarbazepine Tablets USP 150 mg oral tablets, containing 100 tablets per container. The label notes the drug is prescription only and supplied by Advagen Pharma Ltd. Storage and dispensing instructions are included, along with manufacturer information for Rubicon Research Ltd., India. The label features a barcode and space marked as an overprinting area.*

FDA Label Image

Oxcarbazepine-tablets-usp-300mg (Oxcarbazepine Tablets Usp 300mg 100s)

Label for Oxcarbazepine Tablets USP 300 mg oral tablets from Advagen Pharma Ltd., distributed in East Windsor, NJ, and manufactured by Rubicon Research Ltd. The label indicates a package size of 100 tablets, includes storage instructions, and directs to dispense medication guides with each patient. The label features barcodes and a designated overprinting area.*

FDA Label Image

Oxcarbazepine-tablets-usp-600mg (Oxcarbazepine Tablets Usp 600mg 100s)

Label for Oxcarbazepine Tablets USP 600 mg oral tablets by Advagen Pharma Ltd. The label indicates each film-coated tablet contains 600 mg oxcarbazepine. The package contains 100 tablets and is Rx only. Storage instructions and distributor/manufacturer details are provided, including Advagen Pharma Ltd. and Rubicon Research Ltd. The label includes barcodes and a website link for medication guide availability.*

FDA Label Image

Figure 1 Kaplan-meier Estimates Of Exit Rate By Treatment Group (Oxcarbazepine Tablets Usp Graph 1)

A survival curve chart comparing exit rates over time from day 2 to day 11 between oxcarbazepine and placebo treatment groups. The y-axis represents exit rate, and the x-axis shows time in days. The curve for placebo rises more steeply than oxcarbazepine, with a log-rank test p-value of 0.0001 indicating statistical significance.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of First Seizure Event Rate By Treatment Group (Oxcarbazepine Tablets Usp Graph 2)

A Kaplan-Meier survival curve graph showing seizure-free rates over time in days from first dose to first seizure for two treatment groups: Oxcarbazepine and Placebo. The x-axis represents days, and the y-axis represents the seizure rate. The graph includes a log-rank test p-value of 0.046, indicating statistical comparison between the treatment groups.*

FDA Label Image

Figure 3 Kaplan-meier Estimates Of Exit Rate By Treatment Group (Oxcarbazepine Tablets Usp Graph 3)

A survival plot showing exit rates over time for two treatment groups labeled as HIGH and LOW. The X-axis represents time to exit in days, and the Y-axis shows the exit rate. A log-rank test result with p-value 0.0001 is indicated, suggesting a significant difference between the groups.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Exit Rate By Treatment Group (Oxcarbazepine Tablets Usp Graph 4)

A Kaplan-Meier survival curve chart showing the exit rate over time to exit in days for two treatment groups labeled 'HIGH' and 'LOW.' The solid line represents the HIGH treatment group and the dashed line represents the LOW treatment group. A log-rank test p-value of 0.0001 is noted on the chart.*

FDA Label Image

Image (Oxcarbazepine Tablets Usp Structure)

Chemical structure of Oxcarbazepine, showing its molecular framework including a dibenzazepine core with a carbamoyl substitution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.